We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Unique Genetic Makeup of Myeloma Tumor Cells Profiled

By LabMedica International staff writers
Posted on 17 Dec 2018
Multiple myeloma is the second-most common type of blood cancer. More...
Multiple myeloma occurs when plasma cells in the bone marrow, the cells that produce antibodies, proliferate out of control and lead to various type of organ failure and death.

A major stumbling block, in diagnosing myeloma disease is the fact that each patient is unique and current blood tests are incapable of identifying early disease onset and classifying which patient should receive which treatment. Patients whose routine blood tests reveal some hallmarks of the disease in an early and precancerous stage are followed closely with a "watch and wait" strategy, but every year 1% of them will lose in this "Russian roulette" and develop the full-blown myeloma disease.

A large team of international scientists collaborating with the Weizmann Institute of Science (Rehovot, Israel) applied single cell RNA sequencing to study the heterogeneity of 40 individuals along the multiple myeloma progression spectrum, including 11 healthy controls, demonstrating high inter-individual variability that can be explained by expression of known multiple myeloma drivers and additional putative factors.

The new method sequences the RNA in thousands of individual cells from the patient blood or bone marrow, identifying the specific gene program that is active in each individual cell. In order to understand the myeloma cancer blueprint, the scientists first generated a high-resolution model of normal plasma cells by sequencing tens of thousands of cells from healthy individuals undergoing hip-replacements who served as a control group.

The plasma cells of the control patients were highly similar within and across individuals, basically showing a single, common blue print of normal plasma cells. Comparing the normal blueprint to the blue prints of patients, showed that the blueprint of myeloma cancer cells are extremely heterogeneous, with every patient showing its own, unique blueprint and with some patients demonstrating several tumor clones displaying more than a single blueprint in one patient.

The investigators identified extensive subclonal structures for 10 of 29 individuals with multiple myeloma. In asymptomatic individuals with early disease and in those with minimal residual disease post-treatment, they detected rare tumor plasma cells with molecular characteristics similar to those of active myeloma, with possible implications for personalized therapies. Single cell analysis of rare circulating tumor cells allows for accurate liquid biopsy and detection of malignant plasma cells, which reflect bone marrow disease.

Ido Amit, PhD, an immunologist and a leading author of the study, said, “Single cell genomic analysis until now was confined to a small number of research labs, we are constantly pushing the boundaries of the technology in ways that will make it a major clinical discovery and diagnostics tool.” The study was published on December 6, 2018, in the journal Nature Medicine.

Related Links:
Weizmann Institute of Science


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
New
Sample Transportation System
Tempus1800 Necto
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.